Cenerimod clinical trials
Cenerimod is named as an intervention in 5 current clinical trials in our USA, Poland, Mexico, India, Germany, Spain, Czechia, Portugal, China, France, Brazil, South Korea, Taiwan, UK and Japan registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Viatris Innovation GmbH (4). The most-studied condition is Lupus Erythematosus, Systemic. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Cenerimod works
All drug targets →- Sphingosine 1-phosphate receptor Edg-1 modulator ModulatorTarget: S1PR1 sphingosine-1-phosphate receptor 1✓ In ChEMBL and the Guide to Pharmacology
- Lupus nephritisPhase 3
- Systemic lupus erythematosusPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297505, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9824, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Cenerimod
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Cenerimod
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Cenerimod in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Cenerimod. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
2025-522984-14-00 · Immune System Diseases
|
Phase 3 | Authorised | Viatris Innovation GmbH | Germany, Spain, Poland + 2 more |
Conditions studied with Cenerimod
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Viatris Innovation GmbH | 4 |
| Viatris Pharmaceuticals Co., Ltd | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Cenerimod trials
How many clinical trials are testing Cenerimod?
5 current trials in our USA, Poland, Mexico, India, Germany, Spain, Czechia, Portugal, China, France, Brazil, South Korea, Taiwan, UK and Japan registers name Cenerimod (also registered as ACT-334441) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Cenerimod trials recruiting patients?
Yes. 1 of the 5 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Cenerimod clinical trials?
Viatris Innovation GmbH (4) and Viatris Pharmaceuticals Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cenerimod works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cenerimod works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cenerimod (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.